RVMD$123.27
$123.45
Chart
Performance
Key Stats
AI RVMD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralRevolution Medicines, Inc. (RVMD) shows potential in its niche therapeutic area but faces significant profitability challenges and negative sentiment based on current financial data. The stock exhibits mixed technical signals, indicating a holding pattern rather than a strong conviction buy or sell.
Thematic
Revolution Medicines is positioned within the precision oncology and targeted therapy sector, addressing RAS-addicted cancers, a significant area of unmet medical need. The company's focus on novel RAS(ON) and RAS companion inhibitors aligns with trends in personalized medicine and advanced cancer treatments. However, the success is heavily dependent on clinical trial outcomes and future regulatory approvals.
Fundamental
Revolution Medicines exhibits significant financial challenges, characterized by substantial net losses and negative earnings per share. While cash reserves are present, the company is burning cash rapidly, and its revenue generation is minimal, making it highly reliant on future drug approvals and funding. The valuation multiples are not currently supported by fundamental performance.
Technical
The stock is trading below key moving averages and shows weak momentum across various timeframes. Oscillators suggest potential for oversold conditions on shorter timeframes, but the overall trend appears bearish, with resistance levels posing challenges for upward movement.
| Factor | Score |
|---|---|
| Precision Oncology | 85 |
| Drug Pipeline Development | 70 |
| Market Need | 80 |
| Competitive Landscape | 65 |
| Regulatory Pathway | 70 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 5 |
| Balance Sheet Health | 60 |
| Cash Flow | 15 |
| Debt Level | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 45 |
| Price Performance | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Recent Price Performance
The stock has shown mixed short-term performance: -3.12% over 5 days, -0.69% over 1 month, and -8.62% over 6 months. However, it's down -15.41% year-to-date and -19.85% over the last year, indicating a potentially attractive entry point after a decline.
Potential for Undervaluation
The current Price-to-Sales (PS) ratio is 0.0, and the Price-to-Earnings (PE) ratio is null or negative (-12.3 TTM), which is common for clinical-stage companies with no revenue or significant R&D expenses. This can suggest a high growth potential if the company's therapies are successful.
Bearish Points (8)
Consistent Net Losses
The company has reported significant net losses across all reported periods (TTM: -$564.27M, 2024: -$600.09M, 2023: -$436.37M). This is typical for clinical-stage biotechs but indicates no current profitability.
Zero or Negligible Revenue
The company has reported zero or negligible revenue in recent periods (0 for TTM and 2024, $11.58M for 2023). This highlights its reliance on future drug approvals for revenue generation.
Calendar
August 2025
5
Next Earnings Date
H: $-1.02
A: $-1.12
L: $-1.18
H: 250.00M
A: 27.53M
0Profile
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Seasonals
Price Target
72.25 USD
The 39 analysts offering 1 year price forecasts for RVMD have a max estimate of 88.00 and a min estimate of 57.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in HER2-targeted Antibody-Drug Conjugates (ADCs) with Enhertu; strong oncology and immunology pipeline.
Weight: 95
Direct competitor in autoimmune diseases (SLE) with Benlysta, a BLyS inhibitor similar to RVMD's Telitacicept.
Weight: 90
Acquired Seagen, a leader in ADC technology and pipeline, including HER2-targeted therapies and oncology biologics.
Weight: 90
Co-developer of Enhertu (HER2 ADC) and has a strong independent ADC pipeline focusing on multiple cancer types.